Drug intelligence / Profile preview

ENB110e

Development stage: Preclinical
Lead developer: EnnovaBio
Modality: Small Molecules

Overview

ENB110e is a new molecular entity under development by EnnovaBio for the treatment of non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, and primary sclerosing cholangitis. It is classified as an anti-inflammatory and hepatoprotectant agent. The precise mechanism of action has not been defined or disclosed publicly. As of August 2024, it remains in preclinical development with no clinical trials or regulatory approvals reported[1][2].

Other names: ENB 110eENB110eENB-110e

Beyond the preview

Go deeper on ENB110e.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENB110e.

Explore the full profile